Brief: Karolinska Development Portfolio Company AnaCardio Raises SEK 150 Million For Clinical Trial

Kdventures AB

07/09/2022 07:21

Sept 7 (Reuters) - Karolinska Development AB  KDEV.ST :
    * PORTFOLIO COMPANY ANACARDIO RAISES SEK 150 MILLION TO
START
CLINICAL TRIAL WITH CANDIDATE DRUG AC01 IN HEART FAILURE
    * PROCEEDS FROM INVESTMENT ROUND WILL FINANCE PLANNED
CLINICAL
PHASE 1B/2A-STUDY OF ANACARDIO'S LEAD ASSET AC01 IN PATIENTS
WITH HEART FAILURE AND REDUCED EJECTION FRACTION
    * STUDY IS EXPECTED TO BEGIN AT SELECTED CENTERS IN SEVERAL
EUROPEAN COUNTRIES DURING FALL/WINTER OF 2022
    * KAROLINSKA DEVELOPMENT'S OWNERSHIP INTEREST IN ANACARDIO
AMOUNTS
TO 21 PERCENT

Source text for Eikon:  ID:nGNE6G2Lj4 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))